Immuron Travelan® highest sales in history
Immuron (NASDAQ: IMRN) has reported its highest sales figures in history for its over-the-counter immune supplement Travelan®. The company achieved record global sales exceeding AUD$5.3 million year-to-date, marking a 46% increase compared to the previous year.
Regional performance shows strong growth in North America, with quarterly sales of AUD$0.5 million (up 28%) and year-to-date sales of AUD$1.6 million (up 86%). Australian operations recorded AUD$0.8 million for the March 2025 quarter (down 8%), while year-to-date sales reached AUD$3.7 million (up 34%).
Travelan® has achieved significant market positioning in Australia, ranking #1 by market share change and #2 by SKU in the Anti-diarrheal category. The company reports strong momentum in both USA and Canada, with successful direct-to-consumer marketing and major retailer listings respectively.
Immuron (NASDAQ: IMRN) ha riportato i suoi più alti risultati di vendita nella storia per il suo integratore immunitario da banco Travelan®. L'azienda ha raggiunto vendite globali record superiori a AUD$5,3 milioni dall'inizio dell'anno, segnando un aumento del 46% rispetto all'anno precedente.
Le performance regionali mostrano una forte crescita in Nord America, con vendite trimestrali di AUD$0,5 milioni (in aumento del 28%) e vendite dall'inizio dell'anno di AUD$1,6 milioni (in aumento del 86%). Le operazioni australiane hanno registrato AUD$0,8 milioni per il trimestre di marzo 2025 (in calo dell'8%), mentre le vendite dall'inizio dell'anno hanno raggiunto AUD$3,7 milioni (in aumento del 34%).
Travelan® ha ottenuto una posizione di mercato significativa in Australia, classificandosi al #1 per variazione della quota di mercato e al #2 per SKU nella categoria Anti-diarroico. L'azienda riporta un forte slancio sia negli USA che in Canada, con un marketing diretto al consumatore di successo e importanti elenchi presso i rivenditori.
Immuron (NASDAQ: IMRN) ha reportado sus cifras de ventas más altas en la historia para su suplemento inmunológico de venta libre Travelan®. La compañía logró ventas globales récord que superan AUD$5,3 millones en lo que va del año, marcando un aumento del 46% en comparación con el año anterior.
El rendimiento regional muestra un fuerte crecimiento en América del Norte, con ventas trimestrales de AUD$0,5 millones (un 28% más) y ventas acumuladas de AUD$1,6 millones (un 86% más). Las operaciones en Australia registraron AUD$0,8 millones para el trimestre de marzo de 2025 (una disminución del 8%), mientras que las ventas acumuladas alcanzaron AUD$3,7 millones (un 34% más).
Travelan® ha logrado una posición de mercado significativa en Australia, clasificándose en el #1 por cambio en la cuota de mercado y #2 por SKU en la categoría de Anti-diarréico. La empresa informa de un fuerte impulso tanto en EE. UU. como en Canadá, con un exitoso marketing directo al consumidor y listados en importantes minoristas respectivamente.
Immuron (NASDAQ: IMRN)은 자사의 일반의약품 면역 보충제 Travelan®에 대한 역사상 가장 높은 판매 수치를 보고했습니다. 회사는 현재까지 전 세계 판매가 AUD$5.3 백만을 초과하여 작년 대비 46% 증가한 기록을 세웠습니다.
지역 성과는 북미에서 강력한 성장을 보여주며, 분기 판매는 AUD$0.5 백만(28% 증가)이고, 현재까지의 판매는 AUD$1.6 백만(86% 증가)입니다. 호주 운영은 2025년 3월 분기에 AUD$0.8 백만을 기록했으며(8% 감소), 현재까지의 판매는 AUD$3.7 백만(34% 증가)에 도달했습니다.
Travelan®은 호주에서 시장 점유율 변화 기준으로 #1, SKU 기준으로 #2에 올라서는 등 중요한 시장 위치를 확보했습니다. 회사는 미국과 캐나다 모두에서 성공적인 소비자 직접 마케팅과 주요 소매업체 목록을 통해 강력한 모멘텀을 보고하고 있습니다.
Immuron (NASDAQ: IMRN) a rapporté ses chiffres de vente les plus élevés de l'histoire pour son complément immunitaire en vente libre Travelan®. L'entreprise a réalisé des ventes mondiales record dépassant AUD$5,3 millions depuis le début de l'année, marquant une augmentation de 46 % par rapport à l'année précédente.
Les performances régionales montrent une forte croissance en Amérique du Nord, avec des ventes trimestrielles de AUD$0,5 million (en hausse de 28 %) et des ventes depuis le début de l'année atteignant AUD$1,6 million (en hausse de 86 %). Les opérations australiennes ont enregistré AUD$0,8 million pour le trimestre de mars 2025 (en baisse de 8 %), tandis que les ventes depuis le début de l'année ont atteint AUD$3,7 millions (en hausse de 34 %).
Travelan® a obtenu une position de marché significative en Australie, se classant #1 par changement de part de marché et #2 par SKU dans la catégorie Anti-diarrhéique. L'entreprise fait état d'un fort élan tant aux États-Unis qu'au Canada, avec un marketing direct au consommateur réussi et des listes auprès de grands détaillants respectivement.
Immuron (NASDAQ: IMRN) hat die höchsten Verkaufszahlen in der Geschichte seines rezeptfreien Immunpräparats Travelan® gemeldet. Das Unternehmen erzielte bis heute einen Rekordumsatz von über AUD$5,3 Millionen, was einem Anstieg von 46 % im Vergleich zum Vorjahr entspricht.
Die regionale Leistung zeigt ein starkes Wachstum in Nordamerika, mit vierteljährlichen Verkäufen von AUD$0,5 Millionen (plus 28 %) und einem Umsatz von AUD$1,6 Millionen seit Jahresbeginn (plus 86 %). Die australischen Betriebe erzielten im Quartal März 2025 einen Umsatz von AUD$0,8 Millionen (minus 8 %), während der Umsatz seit Jahresbeginn AUD$3,7 Millionen (plus 34 %) erreichte.
Travelan® hat eine bedeutende Marktposition in Australien erreicht und belegt den #1 Platz bei der Veränderung des Marktanteils und den #2 Platz bei SKU in der Kategorie Anti-Durchfallmittel. Das Unternehmen berichtet von einem starken Momentum sowohl in den USA als auch in Kanada, mit erfolgreichem Direktvertrieb an Verbraucher und wichtigen Einzelhandelsauflistungen.
- Record-breaking global sales exceeding AUD$5.3 million YTD (+46% YoY)
- Strong North American performance with 86% YTD sales growth
- Successful Australian market penetration with #1 ranking in market share change
- Expanded pharmacy banner group agreements in Australia
- Successful retail expansion in Canada with major retailer listings
- 8% decline in Australian quarterly sales for March 2025
Insights
Immuron's quarterly results reveal record-breaking performance, with the company surpassing
North America stands out as the growth engine, delivering
For a single-product company of this size, achieving sales equivalent to over half its market capitalization represents significant commercial validation. The strong performance across multiple markets suggests effective execution of their commercial strategy, including expanded pharmacy distribution networks in Australia and refined direct-to-consumer marketing in the USA.
While margin information is absent, the revenue trajectory alone marks a fundamental positive shift for Immuron, especially considering the sustainable growth across multiple quarters rather than a one-time spike. The upcoming travel seasons in both hemispheres provide additional near-term growth catalysts that could further accelerate this positive momentum.
Sales Highlights (unaudited):
| Global |
|
| Australia |
|
| North America |
|
MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Flavio Palumbo, Chief Commercial Officer said, “For the first time, Immuron has exceeded A
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler’s diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler’s Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler’s Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
About Traveler’s diarrhea
Traveler’s Diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information visit: https://www.immuron.com.au
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c358e9d-2229-4518-9fed-43a9f69931bf
FAQ
What are Immuron's (IMRN) latest global sales figures for Travelan in 2025?
How did Travelan perform in North American markets for IMRN in March 2025?
What is Travelan's current market position in Australia's Anti-diarrheal category?
How has IMRN's Travelan performed in the Australian market for 2025?
